The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 02, 2021
Filed:
May. 28, 2020
Applicant:
Aragon Pharmaceuticals, Inc., San Diego, CA (US);
Inventor:
Arturo Molina, Los Altos Hills, CA (US);
Assignee:
Aragon Pharmaceuticals, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61P 35/00 (2006.01); A61K 31/4166 (2006.01); A61K 31/4178 (2006.01); A61K 31/192 (2006.01); A61K 31/4365 (2006.01); A61K 31/496 (2006.01); A61K 31/427 (2006.01); A61K 9/00 (2006.01); A61K 31/4152 (2006.01); A61K 31/4155 (2006.01); A61K 31/426 (2006.01); A61K 31/00 (2006.01); G06Q 30/06 (2012.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 9/0053 (2013.01); A61K 31/00 (2013.01); A61K 31/192 (2013.01); A61K 31/4152 (2013.01); A61K 31/4155 (2013.01); A61K 31/4166 (2013.01); A61K 31/4178 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/4365 (2013.01); A61K 31/496 (2013.01); A61P 35/00 (2018.01); G06Q 30/0607 (2013.01);
Abstract
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.